ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Cellect Biotechnology Ltd

Cellect Biotechnology Ltd (APOPW)

0.0876
0.00
(0.00%)
마감 11 3월 5:00AM
0.00
0.00
(0.00%)
시간외 거래: -

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
0.0876
매수가
0.0001
매도가
0.28
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
market_cap
전일 종가
0.0876
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
-
배당수익률
-
주가수익률
0.00
주당순이익(EPS)
-
매출
-
순이익
-8.69M

Cellect Biotechnology Ltd 정보

섹터
Medicinal Chems,botanicl Pds
산업
Cmp Programming,data Process
웹사이트
본부
Kfar Saba, Center, Isr
설립됨
2007
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

APOPW - Frequently Asked Questions (FAQ)

What is the current Cellect Biotechnology share price?
The current share price of Cellect Biotechnology is US$ 0.0876
What is the 1 year trading range for Cellect Biotechnology share price?
Cellect Biotechnology has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the reporting currency for Cellect Biotechnology?
Cellect Biotechnology reports financial results in USD
What is the latest annual profit for Cellect Biotechnology?
The latest annual profit of Cellect Biotechnology is USD -8.69M
What is the registered address of Cellect Biotechnology?
The registered address for Cellect Biotechnology is 23 HATA’AS STREET, KFAR SABA, CENTER, 44425
What is the Cellect Biotechnology website address?
The website address for Cellect Biotechnology is www.cellect.co
Which industry sector does Cellect Biotechnology operate in?
Cellect Biotechnology operates in the CMP PROGRAMMING,DATA PROCESS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
CAPSCapstone Holding Corp
US$ 3.11
(1,144.00%)
74.5k
HMRHeidmar Maritime Holdings Corporation
US$ 2.5599
(69.53%)
37.58M
RDFNRedfin Corporation
US$ 9.76
(67.70%)
92.54M
CKPTCheckpoint Therapeutics Inc
US$ 3.9895
(61.52%)
60.92M
STSSSharps Technology Inc
US$ 0.4399
(48.26%)
591.61M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.78
(-35.54%)
162.75k
PCLAPicoCELA Inc
US$ 0.8499
(-35.12%)
866.61k
CONLGraniteShares ETF Trust GraniteShares
US$ 15.685
(-34.86%)
8.71M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
US$ 19.22
(-32.95%)
24.19M
JVACoffee Holdings Co
US$ 6.53
(-31.77%)
988.94k
STSSSharps Technology Inc
US$ 0.4399
(48.26%)
591.61M
NVDANVIDIA Corporation
US$ 106.98
(-5.07%)
364.12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.3701
(-30.86%)
258.67M
TSLATesla Inc
US$ 222.15
(-15.43%)
188.57M
TQQQProShares UltraPro QQQ
US$ 59.81
(-11.27%)
155.18M

APOPW Discussion

게시물 보기
INFINITI INFINITI 4 년 전
Is this trading or what ???
👍️0
INFINITI INFINITI 4 년 전
What’s going on here bought @.186 but it’s @.14
👍️0
makinezmoney makinezmoney 5 년 전
$APOPW: L2 looks pretty silly right now



PreMarket Fun action...........




GO $APOPW
👍️0
MWM MWM 5 년 전
Are these exercisable at $6.50? They will be looking good at the open!

https://www.sec.gov/Archives/edgar/data/1671502/000114420416115454/v445455_424b4.htm
👍️0
makinezmoney makinezmoney 5 년 전
$APOPW: $APOP flying this morning on positive NEWS


Warrants should follow suit.


Currenty at $0.09


Should easily get to $0.35



Same as Feb-19 levels.



GO $APOPW
👍️0
02opida 02opida 6 년 전
Cellect Biotechnology
👍️0
midastouch017 midastouch017 8 년 전
Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft™

TEL AVIV, Israel, June 14, 2017 /PRNewswire/ --

PATENT COVERS FIRST-IN-KIND DEVICES FOR SIMPLE AND ROBUST STEM CELL SELECTION REPLACING HIGH-COST AND COMPLEX PROCESSES USED TODAY

Dr. Shai Yarkoni, CEO, commented, "Russia is an multi-billion dollar market opportunity for Cellect's technology licenses."

Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer of stem cells selection technology, announced today that further to the notices of allowance received from the US patent office, the Company has received further confirmation for grant of its patent by the Russian patent authorities (Application No. 2014138001) for a key composition of matter and method of use covering various devices using the ApoGraft for selection of Stem Cells.

Dr. Shai Yarkoni, CEO, commented, "Russia is an important market for us that we believe represents a multi-billion dollar market opportunity for Cellect's technology licenses. This patent is a fundamental base for the future commercialization of our global business and with the US already covered, Russia is the major next country to address. We are aware of the vast stem cell treatment performed nowadays in Russia and therefore believe that our technology will be well-suited this fast-growing demand for stem cells. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, Cellect we believe that has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments."

The device is designed to enable cell selection in a simplified setting by an off-the-shelf product - a solution that currently does not exist and that could potentially cover a wide range of unmet medical needs.

The devices covered by the patent are essentially containers (a bag, column, tube, bottle, vial, flask or bioreactor) comprised of a biocompatible material and a biologically active apoptosis-inducing ligand immobilized to a surface in the inner side of the container. The device is adapted to cell selection of apoptosis-sensitive cells. Specifically, the patent gives the company full protection against any devices that make use of apoptosis for cell selection. It also protects the method for using the device.

Such devices, enable selection for stem-cells and immune cells which support engraftment and negative selection for immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population.

About Cellect Biotechnology Ltd.

Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a breakthrough technology designed to select stem cells from any given tissue, a technology that aims to improve a variety of stem cell applications.

The Company's technology is intended to provide pharma companies, medical research centers and hospitals with tools designed to rapidly select stem cells in quantity and quality that will enable stem-cell related treatments and procedures. Cellect's technology is applicable to a wide variety of stem cell-related treatments in regenerative medicine. The Company's current clinical trials are aimed at the cancer treatment of bone marrow transplantations.
👍️0
wiltonio wiltonio 8 년 전
Askenasy Nadir has filed a new 13G, reporting 12.7% ownership in $APOP - https://fintel.io/so/us/apop
👍️0
ClayTrader ClayTrader 8 년 전
* * $APOP Video Chart 03-27-17 * *

Link to Video - click here to watch the technical chart video
👍️0
biotechnician biotechnician 8 년 전
Easy triple from here.
👍️0
MikeKnowsRunners MikeKnowsRunners 8 년 전
Anyone following yet?
👍️0
MikeKnowsRunners MikeKnowsRunners 8 년 전
Have a good feeling here
👍️0
MikeKnowsRunners MikeKnowsRunners 8 년 전
Welcome to Cellect!!
👍️0
MikeKnowsRunners MikeKnowsRunners 8 년 전
Welcome to Cellect!
👍️0

최근 히스토리

Delayed Upgrade Clock